title: Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome.
abstract: Restless leg syndrome (RLS) is a sensorimotor disorder. Clinical studies have implicated the dopaminergic system in RLS, while others have suggested that it is associated with insufficient levels of brain iron. To date, alterations in brain iron status have been demonstrated but, despite suggestions from the clinical literature, there have been no consistent findings documenting a dopaminergic abnormality in RLS brain tissue. In this study, the substantia nigra and putamen were obtained at autopsy from individuals with primary RLS and a neurologically normal control group. A quantitative profile of the dopaminergic system was obtained. Additional assays were performed on a catecholaminergic cell line and animal models of iron deficiency. RLS tissue, compared with controls, showed a significant decrease in D2R in the putamen that correlated with severity of the RLS. RLS also showed significant increases in tyrosine hydroxylase (TH) in the substantia nigra, compared with the controls, but not in the putamen. Both TH and phosphorylated (active) TH were significantly increased in both the substantia nigra and putamen. There were no significant differences in either the putamen or nigra for dopamine receptor 1, dopamine transporters or for VMAT. Significant increases in TH and phosphorylated TH were also seen in both the animal and cell models of iron insufficiency similar to that from the RLS autopsy data. For the first time, a clear indication of dopamine pathology in RLS is revealed in this autopsy study. The results suggest cellular regulation of dopamine production that closely matches the data from cellular and animal iron insufficiency models. The results are consistent with the hypothesis that a primary iron insufficiency produces a dopaminergic abnormality characterized as an overly activated dopaminergic system as part of the RLS pathology.
authors.affiliation: Department of Neurosurgery, Penn State College of Medicine, Hershey, PA 17033-0850, USA. jconnor@psu.edu
authors.forename: James R
authors.initials: JR
authors.lastname: Connor
authors.forename: Xin-Sheng
authors.initials: XS
authors.lastname: Wang
authors.forename: Richard P
authors.initials: RP
authors.lastname: Allen
authors.forename: John L
authors.initials: JL
authors.lastname: Beard
authors.forename: Jason A
authors.initials: JA
authors.lastname: Wiesinger
authors.forename: Barbara T
authors.initials: BT
authors.lastname: Felt
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Earley
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018798:Anemia, Iron-Deficiency / Q000150:complications / Q000378:metabolism; D000818:Animals; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D011699:Putamen / Q000378:metabolism / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012148:Restless Legs Syndrome / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D013378:Substantia Nigra / Q000378:metabolism / Q000503:physiopathology*; D014407:Tumor Cells, Cultured; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine